Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Department of Drug Sciences, University of Catania, 95125 Catania, Italy.
Int J Mol Sci. 2020 Dec 6;21(23):9305. doi: 10.3390/ijms21239305.
Activation of P2X7 signaling, due to high glucose levels, leads to blood retinal barrier (BRB) breakdown, which is a hallmark of diabetic retinopathy (DR). Furthermore, several studies report that high glucose (HG) conditions and the related activation of the P2X7 receptor (P2X7R) lead to the over-expression of pro-inflammatory markers. In order to identify novel P2X7R antagonists, we carried out virtual screening on a focused compound dataset, including indole derivatives and natural compounds such as caffeic acid phenethyl ester derivatives, flavonoids, and diterpenoids. Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) rescoring and structural fingerprint clustering of docking poses from virtual screening highlighted that the diterpenoid dihydrotanshinone (DHTS) clustered with the well-known P2X7R antagonist JNJ47965567. A human-based in vitro BRB model made of retinal pericytes, astrocytes, and endothelial cells was used to assess the potential protective effect of DHTS against HG and 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate (BzATP), a P2X7R agonist, insult. We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels. Furthermore, HG levels and P2X7R agonist treatment led to increased expression of pro-inflammatory mediators (TLR-4, IL-1β, IL-6, TNF-α, and IL-8) and other molecular markers (P2X7R, VEGF-A, and ICAM-1), along with enhanced production of reactive oxygen species. Treatment with DHTS preserved the BRB integrity from HG/BzATP damage. The protective effects of DHTS were also compared to the validated P2X7R antagonist, JNJ47965567. In conclusion, we provided new findings pointing out the therapeutic potential of DHTS, which is an inhibitor of P2X7R, in terms of preventing and/or counteracting the BRB dysfunctions elicited by HG conditions.
由于高血糖水平的作用,P2X7 信号的激活会导致血视网膜屏障 (BRB) 破裂,这是糖尿病性视网膜病变 (DR) 的一个标志。此外,多项研究报告称,高葡萄糖 (HG) 条件及其相关的 P2X7 受体 (P2X7R) 的激活会导致促炎标志物的过度表达。为了鉴定新型 P2X7R 拮抗剂,我们对包括吲哚衍生物和咖啡酸苯乙酯衍生物、黄酮类和二萜类等天然化合物在内的聚焦化合物数据集进行了虚拟筛选。虚拟筛选中对接构象的分子力学/广义 Born 表面积 (MM/GBSA) 重评分和结构指纹聚类突出表明,二萜二氢丹参酮 (DHTS) 与知名的 P2X7R 拮抗剂 JNJ47965567 聚类在一起。我们使用由视网膜周细胞、星形胶质细胞和内皮细胞组成的基于人类的体外 BRB 模型来评估 DHTS 对 HG 和 2'(3')-O-(4-苯甲酰苯甲酰)腺苷-5'-三磷酸 (BzATP)(P2X7R 激动剂)损伤的潜在保护作用。我们发现,HG/BzATP 暴露通过增强屏障通透性(跨内皮电阻 (TEER))和降低 ZO-1 和 VE-钙粘蛋白连接蛋白以及 Cx-43 mRNA 表达水平来产生 BRB 破裂。此外,HG 水平和 P2X7R 激动剂处理导致促炎介质 (TLR-4、IL-1β、IL-6、TNF-α 和 IL-8) 和其他分子标志物 (P2X7R、VEGF-A 和 ICAM-1) 的表达增加,同时活性氧的产生增加。用 DHTS 处理可防止 HG/BzATP 损伤导致 BRB 完整性受损。DHTS 的保护作用也与经过验证的 P2X7R 拮抗剂 JNJ47965567 进行了比较。总之,我们提供了新的发现,指出 DHTS(一种 P2X7R 抑制剂)在预防和/或对抗 HG 条件引起的 BRB 功能障碍方面具有治疗潜力。